Can statins unlock secrets of a rare liver disease?
NCT ID NCT05912387
First seen Feb 28, 2026 · Last updated Jun 23, 2026 · Updated 17 times
Summary
This early-phase study at Stanford University is testing the statin drug rosuvastatin in 15 people with primary sclerosing cholangitis (PSC), a liver disease with no cure. Researchers want to see how the drug changes bile acids and gut bacteria, hoping to better understand why PSC develops. This is a knowledge-gathering study, not a treatment trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rosuvastatin (a statin drug)
What this could lead to
If successful, this study could reveal how statins change bile acids and gut bacteria in PSC, pointing toward new ways to manage the disease.
What could go wrong
This is a very small, early-phase pilot study with only 15 participants, so results may not apply to everyone. It aims to gather knowledge, not test a treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.